Icon Wealth Advisors LLC Raises Position in ICON Public Limited (NASDAQ:ICLR)

Icon Wealth Advisors LLC increased its stake in shares of ICON Public Limited (NASDAQ:ICLR - Free Report) by 861.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,215 shares of the medical research company's stock after acquiring an additional 11,840 shares during the quarter. Icon Wealth Advisors LLC's holdings in ICON Public were worth $3,797,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Liontrust Investment Partners LLP grew its position in ICON Public by 19.5% during the 2nd quarter. Liontrust Investment Partners LLP now owns 119,728 shares of the medical research company's stock worth $37,531,000 after acquiring an additional 19,546 shares during the last quarter. Kornitzer Capital Management Inc. KS grew its position in ICON Public by 15.9% during the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 95,753 shares of the medical research company's stock worth $30,016,000 after acquiring an additional 13,163 shares during the last quarter. Whittier Trust Co. grew its position in ICON Public by 12.3% during the 3rd quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company's stock worth $1,155,000 after acquiring an additional 441 shares during the last quarter. Sara Bay Financial bought a new stake in shares of ICON Public in the 3rd quarter worth approximately $1,143,000. Finally, SkyView Investment Advisors LLC bought a new stake in shares of ICON Public in the 1st quarter worth approximately $1,021,000. 95.61% of the stock is currently owned by institutional investors.

ICON Public Stock Up 0.7 %

Shares of ICON Public stock traded up $1.49 on Friday, reaching $214.25. The company's stock had a trading volume of 2,528,320 shares, compared to its average volume of 1,913,621. The company has a market capitalization of $17.68 billion, a price-to-earnings ratio of 23.89, a P/E/G ratio of 1.57 and a beta of 1.25. The firm's fifty day simple moving average is $257.93 and its two-hundred day simple moving average is $297.75. ICON Public Limited has a 52 week low of $183.38 and a 52 week high of $347.72. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 0.35.

ICON Public (NASDAQ:ICLR - Get Free Report) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing analysts' consensus estimates of $3.72 by ($0.37). The business had revenue of $2.03 billion during the quarter, compared to the consensus estimate of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The firm's revenue for the quarter was down 1.2% on a year-over-year basis. During the same period in the previous year, the business posted $3.10 EPS. Equities analysts anticipate that ICON Public Limited will post 13.42 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Evercore ISI cut their price objective on ICON Public from $360.00 to $350.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 8th. Leerink Partners reiterated an "outperform" rating and issued a $255.00 price objective (down from $270.00) on shares of ICON Public in a research report on Tuesday. Redburn Atlantic assumed coverage on ICON Public in a research report on Monday, October 14th. They issued a "neutral" rating and a $311.00 price objective on the stock. StockNews.com lowered ICON Public from a "buy" rating to a "hold" rating in a research report on Thursday, September 19th. Finally, Baird R W cut ICON Public from a "strong-buy" rating to a "hold" rating in a research note on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, ICON Public currently has a consensus rating of "Moderate Buy" and a consensus price target of $292.45.

ICON Public Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.